Herceptin News and Research

RSS

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center.

12 Dec 2009

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.

9 Dec 2009

Health leaders to discuss latest breast cancer findings at CTRC-AACR San Antonio Breast Cancer Symposium

Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal of eradicating breast cancer.

4 Dec 2009

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting.

20 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

4 Nov 2009

HER2-positive breast cancer patients can be treated with Trastuzumab and adjuvant radiation therapy

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy.

4 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

Retailers join to support breast cancer research

This October, retailers nationwide are joining the fight against breast cancer by offering pink ribbon products that benefit research, treatment and education programs at City of Hope, one of the nation’s leading cancer research and treatment centers. From skin and hair care treatments to apparel to office products, consumers can feel good about their purchases and help support lifesaving cancer research.

1 Oct 2009

Herceptin News and Research

Combination therapy improves overall survival in women with advanced breast cancer

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

YM BioSciences announces results of collaborative antibody development program

Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium

Health leaders to discuss latest breast cancer findings at CTRC-AACR San Antonio Breast Cancer Symposium

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Sprycel holds hope for treating Src dependent ovarian cancer

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Third-quarter 2009 financial results announced by Halozyme Therapeutics

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Gastric cancer drug market to double to nearly $1.5 billion in 2018

HER2-positive breast cancer patients can be treated with Trastuzumab and adjuvant radiation therapy

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Canadian cardiologists, oncologists team up to fight breast cancer

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Retailers join to support breast cancer research

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News